Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
45
XTLB Quote, Financials, Valuation and Earnings
Last price:
$1.66
Seasonality move
:
19.96%
Day range:
$1.57 - $1.88
52-week range:
$0.77 - $4.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.79x
Volume:
1.1K
Avg. volume:
10.9K
1-year change:
108.84%
Market cap:
$10.2M
Revenue:
--
EPS (TTM):
-$0.03
Analysts' Opinion
-
Consensus RatingXTL Biopharmaceuticals has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, XTL Biopharmaceuticals has an estimated upside of 1495.75% from its current price of $1.88.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $1.88.
Fair Value
-
According to the consensus of 0 analysts, XTL Biopharmaceuticals has 1495.75% upside to fair value with a price target of -- per share.
XTLB vs. S&P 500
-
Over the past 5 trading days, XTL Biopharmaceuticals has overperformed the S&P 500 by 16.69% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
XTL Biopharmaceuticals does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
XTL Biopharmaceuticals has grown year-over-year revenues for 1 quarter straight. In the most recent quarter XTL Biopharmaceuticals reported revenues of --.
Earnings Growth
-
XTL Biopharmaceuticals earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter XTL Biopharmaceuticals reported earnings per share of $0.10.
Enterprise value:
7.9M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
12.55x
EV / Revenue:
--
PEG ratio (5yr expected):
-0.03x
EV / Free cash flow:
-3.19x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
12.55x
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2023-03-31 | 2024-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$1M | -$882K | -$689K | -$251K | -$175K | |
| EBITDA | -$809K | -$2.3M | $630K | -$894K | $501K | |
| Diluted EPS | $0.06 | -$0.51 | -$0.03 | -$0.17 | $0.10 | |
| Period Ending | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $6.9M | $6.9M | $6.2M | $2.9M | $2.5M | |
| Total Assets | $7.3M | $7.3M | $6.6M | $3.3M | $2.9M | |
| Current Liabilities | $244K | $251K | $260K | $241K | $223K | |
| Total Liabilities | $244K | $2.9M | $777K | $241K | $223K | |
| Total Equity | $7M | $4.4M | $5.8M | $3.1M | $2.7M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2012-12-31 | 2013-12-31 | 2014-12-31 | 2013-12-31 | 2014-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$1.5M | -$2.5M | -$2.5M | -$520K | -$674K | |
| Cash From Investing | -$1.2M | $3.3M | $1.5M | -$945K | $516K | |
| Cash From Financing | $4.3M | $317K | $309K | $172K | -- | |
| Free Cash Flow | -$1.6M | -$2.6M | -$2.5M | -$521K | -$674K | |
XTLB
Sector
Market Cap
$10.2M
$46.1M
Price % of 52-Week High
37.68%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
108.84%
-30.52%
Beta (5-Year)
1.156
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$1.63
200-day SMA
Sell
Level
$2.33
Bollinger Bands (100)
Sell
Level
1.78 - 2.6
Chaikin Money Flow
Sell
Level
-37.5M
20-day SMA
Buy
Level
$1.76
Relative Strength Index (RSI14)
Buy
Level
55.25
ADX Line
Buy
Level
18.47
Williams %R
Neutral
Level
-28.125
50-day SMA
Buy
Level
$1.82
MACD (12, 26)
Sell
Level
-0.06
25-day Aroon Oscillator
Sell
Level
-40
On Balance Volume
Neutral
Level
33.3M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren’s syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
Stock Forecast FAQ
In the current month, XTLB has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The XTLB average analyst price target in the past 3 months is --.
-
Where Will XTL Biopharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that XTL Biopharmaceuticals share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About XTL Biopharmaceuticals?
Analysts are divided on their view about XTL Biopharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that XTL Biopharmaceuticals is a Sell and believe this share price will drop from its current level to --.
-
What Is XTL Biopharmaceuticals's Price Target?
The price target for XTL Biopharmaceuticals over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is XTLB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for XTL Biopharmaceuticals is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of XTLB?
You can purchase shares of XTL Biopharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase XTL Biopharmaceuticals shares.
-
What Is The XTL Biopharmaceuticals Share Price Today?
XTL Biopharmaceuticals was last trading at $1.66 per share. This represents the most recent stock quote for XTL Biopharmaceuticals. Yesterday, XTL Biopharmaceuticals closed at $1.88 per share.
-
How To Buy XTL Biopharmaceuticals Stock Online?
In order to purchase XTL Biopharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
